Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 3, Issue 1, 2008, Pages 20-30

  Mohammad, Ramzi ^a   Giri, Anshu ^a   Goustin, Anton Scott ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

A1 Bfl1; Bcl 2; Bcl 2 expression; Bcl w; Bcl XL; Cancer; Mcl 1; Therapeutic gents

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 263; ANTINEOPLASTIC AGENT; APOGOSSYPOLONE; BCL2 RELATED PROTEIN A1; BHI 1 DERIVATIVE; BIM PROTEIN; BL 193; CHELERYTHRINE; CITRININ; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; GOSSYPOL; GX 015070; ISOSORBIDE; OBATOCLAX; OBLIMERSEN; OLIGONUCLEOTIDE; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN BID; PROTEIN DERIVATIVE; PROTEIN INHIBITOR; PROTEIN MCL 1; RIBOZYME; TETROCARCIN A; TW 37; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; CROSS RESISTANCE; DEVELOPMENT; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; FEASIBILITY STUDY; HOMEOSTASIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PATENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; DRUG DESIGN; HUMANS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 38949123709     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489208783478676     Document Type: Review

References (87)

1. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999; 399(6735): 483-87.
2. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87(1): 99-163.
3. Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell 2003; 112(4): 481-490.
4. Zamzami N, Kroemer G. Apoptosis: mitochondrial membrane permeabilization - the (w)hole story? Curr Biol 2003; 13(2): R71-3.
5. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996; 86(1): 147-157.
6. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74(4): 609-619.
7. Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell 1994; 79(2): 189-192.
8. Yang E, Korsmeyer S. Molecular thanatopsis: a discourse on the BCL-2 family and cell death. Blood 1996; 88(2): 386-401.
9. Muchmore SW, Sattler M, Liang H, et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996; 381(6580): 335-341.
10. Shangary S, Oliver CL, Tillman TS, Cascio M, Johnson DE. Sequence and helicity requirements for the proapoptotic activity of Bax BH3 peptides. Mol Cancer ther. 2004; 3(11): 1343-1354.
11. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281(5381): 1322-1326.
12. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281(5381): 1309-1312.
13. Gross-A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998; 17(14): 3878-3885.
14. Gereste O, Hickman J, Bennett R, Rain J.-C.: WO06014638 (2006).
15. Chittenden T, Flemington C, Houghton AB, et al. A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death And protein binding functions. EMBO J 1995; 14(22): 5589-5596.
16. Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Genes Develop 1996; 10(22): 2859-2869.
17. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2(3): 183-192.
18. Kelekar A, Thompson CB. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol 1998; 8(8): 324-330.
19. Huang DC, Strasser A. BH3-Only proteins-essential initiators of apoptotic cell death. Cell 2000; 103(6): 839-842.
20. Huang DC, Adams JM, Cory S. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J 1998; 17(4): 1029-1939.
21. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Seminars Cancer Biol 1993; 4(6): 327-3232.
22. Sedlak TW, Oltvai ZN, Yang E, et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 1995; 92(17): 7834-7838.
23. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80(2): 285-291.
24. Acehan D, Jiang X, Morgan DG, Heuser JE, Wang X, Akey CW. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol Cell 2002; 9(2): 423-432.
25. Zou H, Li Y, Liu X, Wang, X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999; 274(17): 11549-11556.
26. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Ann Rev Immunol 1998; 16: 395-419.
27. Reed JC. Bcl-2 family proteins. Oncogene 1998; 17(25): 3225-3236.
28. Reed JC. Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. Adv Pharmacol 1997; 41: 501-532.
29. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292(5517): 727-7230.
30. Cheng EH, Wei MC, Weiler S, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 2001; 8(3): 705-711.
31. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes & dev. 2001; 15(12): 1481-1486.
32. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108(2): 153-164.
33. Solary E, Bettaieb A, Dubrez-Daloz L, Corcos L. Mitothondria as a target for inducing death of malignant hematopoietic cells. Leuk Lymphoma 2003; 44(4): 563-574.
34. Hinz S, Trauzold A, Boenicke L, et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 2000; 19(48): 5477-5486.
35. Duesberg P. Chromosomal chaos and cancer. Sci Am 2007; 296(5): 52-59.
36. Heng HH, Bremer SW, Stevens J, et al. Cancer progression by non-clonal chromosome aberrations. J Cell Biochem 2006; 98(6): 1424-1435.
37. Heng HH, Liu G, Bremer S, Ye KJ, Stevens J, Ye CJ. Clenal and non-clonal chromosome aberrations and genome variation and aberration. Genome/ National Research Council Canada = Gegome/Conseil National de Recherches Canada 2006; 49(3): 195-204.
38. Heng HH, Stevens JB, Liu G, et al. Stochastic cancer progression driven by non-clonal chromosome aberrations.. J Cell Physiol 2006; 208(2):461-472.
39. Garcia A, Cayla X, Rebollo A.: EP1788394 (2007).
40. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 2003; 39(11): 615-647.
41. Lee JU, Hosotani R, Wada M, et al. Role of Bcl-2 family proteins (Bax, Bcl-2 and Bcl-X), on cellular susceptibility to radiation in pancreatic cancer cells. Eur J Cancer 1999; 35(9): 1374-1380.
42. Simonian PL, Grillot DA, Nunez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 1997; 90(3): 1208-1216.
43. Reed JC, Miyashita T, Takayama S, et al. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996; 60(1): 23-32.
44. Geneste, O., Hickman, J., Bennett, R., Rain, J.-C.: EP1651668. (2006).
45. Cotter FE. Antisense therapy for lymphomas. Hematol Oncol 1997, 15(1): 3-11.
46. Morris MJ, Tong WP, Cordon-Cardo C, et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002; 8(3): 679-683.
47. Mohammad R, Abubakr Y, Dan M, et al. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14; 18) follicular lymphoma. Clin Cancer Res 2002; 8(4): 1277-1283.
48. Piche A, Grim J, Rancourt C, Gomez-Navarro J, Reed JC, Curiel DT. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res 1998; 58(10): 2134-2140.
49. Wang JL, Zhang ZJ, Choksi S, et al. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res 2000; 60(6): 1498-1502.
50. Oltersdorf T, Elmore SW, Shoemaker AN, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435(7042): 677-681.
51. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10(5): 389-399.
52. Lock R, Carol H, Houghton PJ, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 2007.
53. Wilson WH, Tulpule A, Levine AM, et al. A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Refractory or Relapsed Lymphoid Malignancies. Blood (ASH Annual Meeting Abstracts), 2007; 110(11): 1371-1374.
54. Bushunow P. Reidenberg MM, Wasenko J, et al. Gossypol treatment of recurrent adult malignant gliomas. Journal of neuro-oncology. 1999 May, 43(1): 79-86.
55. Stein RC, Joseph AE, Madin SA, Cunningham DC, Ford HT, Coombes RC. A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother Pharmacol 1992; 30(6): 480-482.
56. Wang G, Nikolovska-Coleska Z, Yang CY, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006; 49(21): 6139-6142.
57. Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 2007; 109(12): 5430-5438.
58. Borthakur G, O'Brien S, Ravandi-Kashani F, et al. A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by 24 Hour Infusion Every 2 Weeks to Patients with Myeloid Malignancies and Chronic Lymphocytic Leukemia (CLL), Poster Board #-Session: 832-II. Blood (ASH Annual Meeting Abstracts) 2006 108: Abstract 2654. 2006; 108.
59. Mohammad RM, Goustin AS, Aboukameel A, et al. Preclinical studies of TV-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res. 2007; 13(7): 2226-2235.
60. Zeitlin BD, Joo E, Dong Z, et al. Antiangiogenic Effect of TW37, a Small-Molecule Inhibitor of Bcl-2. Cancer Res 2006; 66(17): 8698-8706.
61. Zhang X, Ling Y, Zhang Y, et al. A novel pan inhibitor of Bcl-2 and Mcl-1 Apogossypolone (ApoG2) with superior stability and improved activity against human leukemia and lymphoma cells. Ascenta Therapeutics, Inc. San Diego, CA.
62. Mohammad R, Young D, Chen B, et al. ApoG2, a potent, nontoxic small-molecule inhibitor of Bcl-2 family: A preclinical trial in lymphoma. University of Michigan. Ann Arbor, MI.
63. Wang. JL, Liu D, Zhang ZJ, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000; 97(13): 7124-9.
64. Baell JB, Huang DC. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem Pharmacol 2002 Sep; 64(5-6): 851-63.
65. Kaneko M, Nakashima T, Uosaki Y, Hara.M, Ikeda S, Kanda Y. Synthesis of tetrocarcin derivatives with specific inhibitory activity towards Bcl-2 functions. Bioorg Med Chem Lett 2001; 11(7): 887-890.
66. Enyedy IJ, Ling Y, Nacro K, et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 2001; 44(25):4313-4324.
67. Tinhofer I, Anether G, Senfter M. et al. Stressful death of T-ALL tumor cells after treatment with the anti-tumor agent Tretrocarcin-A. FASEB J 2002; 16(10): 1295-1297.
68. Chmura SJ, Dolan ME, Cha A, Mauceri HJ, Kufe DW, Weichselbaum RR. In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxidity and growth delay in vivo. Clin Cancer Res 2000; 6(2): 737-742.
69. Chan SL, Lee MC, Tan KO, et al. Identification of chelerythrine as an inhibitor of Bc1XL function. J Biol Chem 2003; 278(23): 20453-20456.
70. Zhang YH, Bhunia A, Wan KF, et al. Chelerythrine and sanguinarine dock at distinct sites on Bc1XL that are not the classic BH3 binding cleft. J Mol Biol 2006 Dec 1; 364(3): 536-549.
71. Tzung SP, Kim KM, Basanez G. et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001; 3(2): 183-191.
72. Manion MK, O'Neill JW, Giedt CD, Kim KM, Zhang KY. Hockenbery DM. Bcl-XL mutations suppress cellular sensitivity to antimycin A. J Biol Chem 2004; 279(3): 2159-2165.
73. Chen M, Xing D, Chen T, Zhang L. BimL involvement in Bax activation during UV irradiation-induced apoptosis. Biochem Biophys Res Commun 2007; 358(2): 559-565.
74. Xing C, Wang L, Tang X, Sham YY. Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1. Bioorg Med Chem 2007; 15(5): 2167-2176.
75. Frantz S. Drug discovery: playing dirty. Nature 2005; 437(7061): 942-943.
76. Guida T, Anaganti S, Provitera L, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res 2007; 13(11): 3363-3369.
77. Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, Cools J. The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica 2007; 92(1): 27-34.
78. Plaza-Menacho I, Mologni L, Sala E, et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 2007.
79. Tradel S, Stewart AK, Li Z, et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimy-eloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 2007; 13(2 Pt 1): 621-629.
80. Mohammad RM, Wang S, Banerjee S, Wu X, Chen J, Sarkar FH. Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (-)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line. Pancreas 2005; 31(4): 317-324.
81. Mohammad RM, Wang S, Aboukameel A, et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol Cancer Therapeut 2005; 4(1): 13-21.
82. Perez-Galan P, Roue G, Villamor N, Campo E, Colomer D. The BH3 -mimetic GX15-070 synergizes wi(h bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007; 109(10): 4441-4449.
83. Shoemaker AR, Mitten MJ, Oleksijew A, et al. The Bcl-2 Family Inhibitor ABT-263 Shows Significant Anti-Tumor Efficacy in Models of B Cell Non-Hodgkins Lymphoma. Blood (ASH Annual Meeting Abstracts) 2007: Abstract 825. 2007.
84. Tahir SK, Yang X, Anderson MG, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-787. Cancer Res 2007; 67(3). 1176-1183.
85. Doshi JM, Tian D, Xing C. Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H- chromene-3-carboxylate (HA 14-1), a Prototype Small-Molecule Antagonist against Antiapoptotic Bcl-2 Proteins, Decomposes To Generate Reactive Oxygen Species That Induce Apoptosis. Mol Pharmaceut 2007; 4(6): 919-928.
86. Doshi JM, Tian D, Xing C. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3- carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer. J Med Chem 2006; 49(26): 7731-7739.
87. Tian D, Das SG, Doshi JM, Peng J, Lin J, Xing C. sHA 14-1, a stable. and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell. Cancer Lett 2008; 259(2): 198-208.